CoChat

SL-scan identifies synthetic lethal interactions in cancer using metabolic networks

Zangene, Ehsan, Marashi, Sayed-Amir, Montazeri, Hesam · 2023 · Scientific Reports
Cited by 8

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Exploiting synthetic lethality is a promising strategy for developing targeted cancer therapies. However, identifying clinically significant synthetic lethal (SL) interactions among a large number of gene combinations is a challenging computational task. In this study, we developed the SL-scan pipeline based on metabolic network modeling to discover SL interaction. The SL-scan pipeline identifies the association between simulated Flux Balance Analysis knockout scores and mutation data across cancer cell lines and predicts putative SL interactions. We assessed the concordance of the SL pairs predicted by SL-scan with those of obtained from analysis of the CRISPR, shRNA, and PRISM datasets. Our results demonstrate that the SL-scan pipeline outperformed existing SL prediction approaches based on metabolic networks in identifying SL pairs in various cancers. This study emphasizes the importance of integrating multiple data sources, particularly mutation data, when identifying SL pairs for targeted cancer therapies. The findings of this study may lead to the development of novel targeted cancer therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-023-42992-4

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 48

  1. Zhao, W. et al. Large-scale characterization of drug responses of clinically relevant proteins in cancer cell lines. Cancer Cell 38, 829-843.e4 (2020). · DOI
  2. Srivatsa, S. et al. Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens. Nat. Commun. 13, 7748 (2022). · DOI
  3. Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779–1784 (2017). · DOI · Paper page
  4. Montazeri, H. et al. Systematic identification of novel cancer genes through analysis of deep shRNA perturbation screens. Nucleic Acids Res. 49, 8488–8504 (2021). · DOI · Paper page
  5. Lin, C.-H. & Lichtarge, O. Using interpretable deep learning to model cancer dependencies. Bioinformatics 37, 2675–2681 (2021). · DOI
  6. Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564-576.e16 (2017). · DOI · Paper page
  7. Iglehart, J. D. & Silver, D. P. Synthetic lethality–a new direction in cancer-drug development. N. Engl. J. Med. 361, 189–191 (2009). · DOI · Paper page
  8. Lord, C. J. & Ashworth, A. PARP Inhibitors: the first synthetic lethal targeted therapy. Science 355, 1152 (2017). · DOI · Paper page
  9. Li, S. et al. Development of synthetic lethality in cancer: molecular and cellular classification. Signal Transduct Target Ther 5, 241 (2020). · DOI · Paper page
  10. Shieh, G. S. Harnessing synthetic lethal interactions for personalized medicine. J Pers Med 12, (2022). · DOI
  11. Bender, A. & Pringle, J. R. Use of a screen for synthetic lethal and multicopy suppressee mutants to identify two new genes involved in morphogenesis in Saccharomyces cerevisiae. Mol. Cell. Biol. 11, 1295–1305 (1991).
  12. Sinha, S. et al. Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nat. Commun. 8, 15580 (2017). · DOI
  13. Yizhak, K. et al. Phenotype-based cell-specific metabolic modeling reveals metabolic liabilities of cancer. Elife 3, (2014). · DOI · Paper page
  14. Agren, R. et al. Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol. Syst. Biol. 10, 721 (2014). · DOI · Paper page
  15. Paul, A. et al. Exploring gene knockout strategies to identify potential drug targets using genome-scale metabolic models. Sci. Rep. 11, 213 (2021). · DOI
  16. Apaolaza, I. et al. An in-silico approach to predict and exploit synthetic lethality in cancer metabolism. Nat. Commun. 8, 459 (2017). · DOI
  17. Bidkhori, G. et al. Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes. Proc. Natl. Acad. Sci. U. S. A. 115, E11874–E11883 (2018). · DOI · Paper page
  18. Sun, L., Suo, C., Li, S.-T., Zhang, H. & Gao, P. Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect. Biochim. Biophys. Acta Rev. Cancer 1870, 51–66 (2018). · DOI · Paper page
  19. von Kamp, A. & Klamt, S. Enumeration of smallest intervention strategies in genome-scale metabolic networks. PLoS Comput. Biol. 10, e1003378 (2014). · DOI · Paper page
  20. Apaolaza, I. et al. A network-based approach to integrate nutrient microenvironment in the prediction of synthetic lethality in cancer metabolism. PLoS Comput. Biol. 18, e1009395 (2022). · DOI
  21. Hartman, H. B. et al. Identification of potential drug targets in Salmonella enterica sv. Typhimurium using metabolic modelling and experimental validation. Microbiology 160, 1252–1266 (2014). · DOI
  22. Navid, A. Applications of system-level models of metabolism for analysis of bacterial physiology and identification of new drug targets. Brief. Funct. Genomics 10, 354–364 (2011). · DOI
  23. Pratapa, A., Balachandran, S. & Raman, K. Fast-SL: an efficient algorithm to identify synthetic lethal sets in metabolic networks. Bioinformatics 31, 3299–3305 (2015). · DOI
  24. Ghandi, M. et al. Next-generation characterization of the cancer cell line Encyclopedia. Nature 569, 503–508 (2019). · DOI · Paper page
  25. Noronha, A. et al. The Virtual Metabolic Human database: integrating human and gut microbiome metabolism with nutrition and disease. Nucleic Acids Res. 47, D614–D624 (2019). · DOI · Paper page
  26. Jamialahmadi, O., Hashemi-Najafabadi, S., Motamedian, E., Romeo, S. & Bagheri, F. A benchmark-driven approach to reconstruct metabolic networks for studying cancer metabolism. PLoS Comput. Biol. 15, e1006936 (2019). · DOI
  27. Orth, J. D., Thiele, I. & Palsson, B. Ø. What is flux balance analysis?. Nat. Biotechnol. 28, 245–248 (2010). · DOI · Paper page
  28. Joshi, C. J. et al. StanDep: Capturing transcriptomic variability improves context-specific metabolic models. PLoS Comput. Biol. 16, e1007764 (2020).
  29. Zur, H., Ruppin, E. & Shlomi, T. iMAT: an integrative metabolic analysis tool. Bioinformatics 26, 3140–3142 (2010). · DOI · Paper page
  30. Opdam, S. et al. A Systematic evaluation of methods for tailoring genome-scale metabolic models. Cell Syst 4, 318-329.e6 (2017). · DOI · Paper page
  31. Shao, D. D. et al. ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res. 23, 665–678 (2013). · DOI · Paper page
  32. Gao, Y. et al. Knockdown of RRM1 in tumor cells promotes radio-/chemotherapy induced ferroptosis by regulating p53 ubiquitination and p21-GPX4 signaling axis. Cell Death Discov 8, 343 (2022). · DOI
  33. Shu, Z. et al. Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition. Oncogene 39, 5721–5733 (2020). · DOI
  34. Ramamoorthy, K., Sabui, S., Manzon, K. I., Balamurugan, A. N. & Said, H. M. miR-122–5p is involved in post-transcriptional regulation of the mitochondrial thiamin pyrophosphate transporter (SLC25A19) in pancreatic acinar cells. American Journal of Physiology-Gastrointestinal and Liver Physiology (2023) doi:https://doi.org/10.1152/ajpgi.00106.2023. · DOI
  35. Chen, X. et al. STAT5A modulates CDYL2/SLC7A6 pathway to inhibit the proliferation and invasion of hepatocellular carcinoma by targeting to mTORC1. Oncogene 41, 2492–2504 (2022). · DOI
  36. Henkels, K. M., Muppani, N. R. & Gomez-Cambronero, J. PLD-specific small-molecule inhibitors decrease tumor-associated macrophages and neutrophils infiltration in breast tumors and lung and liver metastases. PLoS ONE 11, e0166553 (2016). · DOI · Paper page
  37. Brown, H. A., Thomas, P. G. & Lindsley, C. W. Targeting phospholipase D in cancer, infection and neurodegenerative disorders. Nat. Rev. Drug Discov. 16, 351–367 (2017). · DOI · Paper page
  38. Kadlubar, F. F. et al. The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer Epidemiol. Biomarkers Prev. 12, 327–331 (2003).
  39. Huang, H. et al. SLC15A4 serves as a novel prognostic biomarker and target for lung adenocarcinoma. Front. Genet. 12, 666607 (2021).
  40. Li Petri, G. et al. Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds. Br. J. Cancer 123, 644–656 (2020). · DOI
  41. Sharaf, R. N. et al. Computational prediction and experimental validation associating FABP-1 and pancreatic adenocarcinoma with diabetes. BMC Gastroenterol. 11, 5 (2011). · DOI
  42. Bang, Y.-J. Capecitabine in gastric cancer. Expert Rev. Anticancer Ther. 11, 1791–1806 (2011). · doi:10.1586/era.11.172
  43. Okines, A., Chau, I. & Cunningham, D. Capecitabine in advanced gastric cancer. Expert Opin. Pharmacother. https://doi.org/10.1517/14656566.8.16.2851 (2007). · DOI
  44. Wang, J. et al. Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. Oncogene 40, 4894–4905 (2021). · DOI
  45. Choksi, A. et al. Tumor suppressor SMAR1 regulates PKM alternative splicing by HDAC6-mediated deacetylation of PTBP1. Cancer Metab 9, 16 (2021). · DOI
  46. Xiao, D. et al. Inhibitory role of proguanil on the growth of bladder cancer via enhancing EGFR degradation and inhibiting its downstream signaling pathway to induce autophagy. Cell Death Dis. 13, 499 (2022). · doi:10.1038/s41419-022-04937-z
  47. Zhang, N., Sundquist, J., Sundquist, K. & Ji, J. Proguanil and atovaquone use is associated with lower colorectal cancer risk: a nationwide cohort study. BMC Med. 20, 1–10 (2022). · DOI
  48. Sun, J. et al. Whole transcriptome analysis of chemically induced hepatocellular carcinoma using RNA-sequencing analysis. FEBS Open Bio 9, 1900–1908 (2019). · DOI

Cited by

See all 8

Metadata

Authors
Zangene, E., Marashi, S.-A., & Montazeri, H.
Venue
Scientific Reports
Published
2023-09-22
Volume
13
Issue
1
ISSN
2045-2322
Cited by
8
References
5
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SL-scan identifies synthetic lethal interactions in cancer using metabolic networks. https://app.cochat.ai/papers/10.1038/s41598-023-42992-4
The paper
Zangene, E., Marashi, S.-A., & Montazeri, H. (2023). SL-scan identifies synthetic lethal interactions in cancer using metabolic networks. Scientific Reports. https://doi.org/10.1038/s41598-023-42992-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.